KYKOY

Kyowa Kirin Co., Ltd.

KYKOY, USA

Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachromatic leukodystrophy; Orkedia for treatment of secondary hyperparathyroidism; and Romiplate to treat aplastic anemia. It also develops OTL-203 for the treatment of mucopolysaccharidosis type IH (hurler syndrome); KHK4083/AMG 451 to treat atopic dermatitis, prurigo nodularis, and asthma; OTL-201 for the treatment of mucopolysaccharidosis type IIIA (sanfilippo syndrome type A); ziftomenib for treating R/R acute myeloid Leukemia and acute lymphoblastic leukemia; KHK4951 for the treatment of diabetic macular edema and neovascular age-related macular degeneration; KK8123 to treat x-linked hypophosphatemia; KK2845 for the treatment of acute myeloid leukemia; KK4277 for treating systemic and cutaneous lupus erythematosus; Lumicef to treat palmoplantar pustulosis; KK2260 and KK2269 for the treatment of solid tumors; and KK8398 for the treatment of achondroplasia. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

https://www.kyowakirin.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
KYKOY
stock
KYKOY

BridgeBio Stock: Next Chapter Begins After Attruby Approval (NASDAQ:BBIO) Seeking Alpha

Read more →
KYKOY
stock
KYKOY

Why The Small Orchard Therapeutics Buyout Is Worth A Look (NASDAQ:ORTX) Seeking Alpha

Read more →

Finn Analysis

(Last Updated 2024-06-30)

Health Score

Price to Earnings Ratio (P/E)

-

Medium

30.81

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.01

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

2.68 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.16 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

0.96 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.24

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Kyowa Kirin Co., Ltd.

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

—

EPS Actual

—

EPS Estimate

—

EPS Difference

—

Surprise Percent

undefined%

Investing Fit Scorecard

(Last Updated 2024-06-30)

Deep Value
Strong Deep Value(9)
Defensive
Highly Defensive(7.5)
Dividend
Decent Dividend Payer(5)
Economic Moat
Wide Moat Company(8.3)
GARP
Strong GARP(8)
Growth
High Growth(6.5)
Momentum
Moderate Momentum(5.5)
Net Net
Strong Net-Net(9.5)
Quality
High Quality(8)
Value
Undervalued(8)

Income Statement

(Last Updated 2024-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.